| Filed On | Filing |
|---|---|
| 31 Jul 2026 |
8-K/A: Financial Statements and Exhibits
On May 18, 2026 (the “Closing Date”), Neurocrine Biosciences, Inc. (“Neurocrine” or the “Company”) completed the previously announced acquisition (the “Acquisition” or “Transaction”) of Soleno Therapeutics, Inc. (“Soleno”). On May 14, 20... |
| 07 Sep 2017 | 8-K/A: Submission of Matters to a Vote of Security Holders |
| 27 Jul 2005 | 8-K/A: Financial Statements and Exhibits |
Loading...
